Comparative study of the validity of four French McGill Pain Questionnaire (MPQ) versions

Boureau, F.; Luu, Mai; Doubrère, J.-F.

doi:10.1016/0304-3959(92)90112-o

Cited by 130 publications

(69 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Subsets were chosen with no consideration of an underlying neural network. Additional information derived from the McGill Pain Questionnaire (Boureau et al 1992), using forced single choice answers, bore on the temporality, and depth of the symptoms. Symptoms were recognized as either ''brief-transient'' or ''periodic-intermittent'' or ''continuous-constant'' to describe their dominant connection with time.…”

Section: Sensory and Psychological Datamentioning

confidence: 99%

“…Session-dependent questionnaires (Q6-Q8) Three questionnaires were filled retrospectively at the end of the test day, featuring Q6: the Profile Of Mood States (POMS), a French adaptation (Fillion and Gagnon 1999) of the abridged profile of mood states by Shacham (1983), Q7: the Questionnaire de Douleur de Saint-Antoine (QDSA), a validated French version of the McGill Pain Questionnaire (Boureau et al 1992) that describes sensory and emotional dimensions of pain, and Q8: the Spielberger State Anxiety Inventory (SAI; Spielberger et al 1983). Mood and anxiety were monitored to account for the potential input of affective states on sensory scores (Villemure and Bushnell 2002).…”

Section: Sensory and Psychological Datamentioning

confidence: 99%

See 1 more Smart Citation

Effect of slow-release β-alanine tablets on absorption kinetics and paresthesia

et al. 2011

View full text Add to dashboard Cite

Oral β-alanine (βA) doses larger than 800 mg commonly result in unpleasant sensory symptoms (paresthesia). However, the association of form (pure vs. slow-release) with side-effects has not been fully described. The aim of this single-blinded, randomized three-arm clinical trial was to compare plasma kinetics and symptoms following βA bolus administration in solution or in slow-release tablet form. Eleven healthy adults ingested 1.6 g of a pure βA reference solution (REF), 1.6 g in slow-release βA tablets (TAB) or a placebo (PLA) after an overnight fast. During the next 6 h, urinary and plasma βA concentrations were measured and questionnaires about intensity, nature (pins and needles, itching, flushing, irritation, numbness, soreness), and spatial distribution of unusual sensations were filled in. TAB resulted in a smaller peak plasma concentration than REF (82 vs. 248 μmol L(-1), p<0.001), delayed time to peak (1.0 vs. 0.5 h, p<0.01) no difference in area under the curve, reduced loss in urine (202 vs. 663 μmol, p<0.0001), and improved retention (98.9 vs. 96.3%, p<0.001). Symptoms described as "pins and needles" were perceived rapidly on the skin of the arms and trunk after REF (Tmax=15 min) and their time course nearly mimicked plasma concentrations. Maximum intensity scores were weaker with TAB ("very low") than with REF ("low", p<0.001), while TAB and PLA did not differ with respect to side-effects. In summary, ingesting 1.6 g βA in slow-release tablets rather than pure in solution results in slower absorption kinetics, improved whole body retention and sensory side-effects that cannot be differentiated from PLA.

show abstract

Section: Sensory and Psychological Datamentioning

confidence: 99%

Section: Sensory and Psychological Datamentioning

confidence: 99%

Effect of slow-release β-alanine tablets on absorption kinetics and paresthesia

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Pain intensity was evaluated by a Visual Analog Scale (VAS), the Questionnaire Douleur de Saint-Antoine scale (QDSA; the validated French version of the McGill Pain Questionnaire) (10), and the Tubingen Pain Behavior Scale (TBS) (11). QDSA measures the different components of the subjective pain experience, describing the sensory and the affective dimensions.…”

Section: Patients and Control Subjectsmentioning

confidence: 99%

“…We performed a whole-brain voxel-based analysis to determine the relationship between regional cerebral blood flow (rCBF) and clinical parameters related to pain, disability, and anxiety and depression status (9)(10)(11)(12). These cerebral areas of correlation were compared with areas of significant hypo-and hyperperfusion found through comparisons with healthy subjects.…”

mentioning

confidence: 99%

Clinical Correlate of Brain SPECT Perfusion Abnormalities in Fibromyalgia

Guedj

Cammilleri²,

Niboyet³

et al. 2008

J Nucl Med

View full text Add to dashboard Cite

The purpose of this study was to investigate the specific clinical correlate of brain SPECT perfusion abnormalities reported in fibromyalgia. Methods: We performed a whole-brain voxel-based correlation analysis involving regional cerebral blood flow and various parameters related to pain (Visual Analog Scale, Tubingen Pain Behavior Scale, and Questionnaire Douleur de Saint-Antoine Scale), disability (Fibromyalgia Impact Questionnaire [FIQ]), and anxiety and depression status (Hospital Anxiety and Depression scale) in 20 patients with fibromyalgia (P voxel , 0.005). Ten healthy control women were also included, in order to determine areas of significant hypo-and hyperperfusions in patients. Results: FIQ total score was positively correlated with bilateral parietal perfusion, including postcentral cortex. These clusters of correlation were included in the areas of significant hyperperfusion. FIQ total score was also negatively correlated with perfusion of a left anterior temporal cluster, included in the areas of significant hypoperfusions. No other clinical correlation was observed with regional cerebral blood flow. Conclusion: These results show that brain perfusion abnormalities in patients with fibromyalgia are correlated with the clinical severity of the disease.

show abstract

“…Content validity is similar to that of the full-length MPQ [28]. A short 15-item version has been developed and is awaiting evaluation [28] (Appendix 2).…”

Section: Metrologymentioning

confidence: 96%

Pain assessment in rheumatology – How can we do better? A literature review

2016

View full text Add to dashboard Cite

Patients' symptoms have a place of prominence in the rheumatology landscape, and among them pain is the most conspicuous. Several pain assessment tools have been validated. Onedimensional pain scales such as visual analog scales (VASs) and numeric rating scales (NRSs) are fast to administer but have limitations that must be acknowledged. Some clinical situations require the use of multidimensional scales such as the McGill Pain Questionnaire or the Multidimensional Pain Inventory (MPI). These tools allow the assessment and management of the diverse components of pain. Here, we review the main patient-reported outcomes that can serve to evaluate pain and the psychometric properties of pain assessment tools. We also discuss the selection of the tool most appropriate for each situation (e.g., everyday practice and research).

show abstract

Comparative study of the validity of four French McGill Pain Questionnaire (MPQ) versions

Cited by 130 publications

References 14 publications

Effect of slow-release β-alanine tablets on absorption kinetics and paresthesia

Effect of slow-release β-alanine tablets on absorption kinetics and paresthesia

Clinical Correlate of Brain SPECT Perfusion Abnormalities in Fibromyalgia

Pain assessment in rheumatology – How can we do better? A literature review

Contact Info

Product

Resources

About